logo
logo
HLN stock ticker logo

Haleon plc

NYSE•HLN
CEO: Mr. Brian James McNamara
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 2022-07-25
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Contact Information
The Heights, Building 5, First Floor, Weybridge, KT13 0NY, United Kingdom
44-1932-822000
www.haleon.com
Market Cap
$41.25B
P/E (TTM)
30.0
27.7
Dividend Yield
2.1%
52W High
$11.42
52W Low
$8.71
52W Range
21%
Rank34Top 27.8%
4.7
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Average • 4.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025

Financial Dashboard

Q4 2025 Data

Revenue

$7.39B+0.00%
4-Quarter Trend

EPS

$0.25+0.00%
4-Quarter Trend

FCF

$1.68B+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Operating Profit Rises Strongly Operating profit £2.4B, achieving 9.3% growth; Organic operating profit margin reached 10.5% versus 5.0% prior year.
Revenue Declines Slightly Revenue £11.0B, down 1.8% compared to 2024; Basic EPS grew to 18.6p from 15.8p previously reported.
Strong Cash Flow Generation Net cash inflow from operating activities £2.6B; Total borrowings net debt leverage remains stable at 2.6x Adjusted EBITDA.

Risk Factors

Intense Market Competition Risks Private label growth and consumer preference shifts threaten market share; execution failure risks brand loyalty erosion.
Geopolitical Supply Chain Volatility Geopolitical instability, trade barriers, and inflation increase input costs and disrupt global supply chain operations.
Cyber Security Threat Escalation Increased cyber-attacks risk operational disruption; investment in security culture and technology remains critical focus area.

Outlook

Executing Win As One Strategy Focus remains on delivering growth, productivity, and culture agenda; new operating model expected to yield £175M-£200M savings.
ESG Targets Progress Focus Aiming for 55% Scope 1 and 2 carbon reduction by 2030; committed to reducing virgin plastic use by 50% by 2030.
Shareholder Return Commitment Board proposed 4.9p final dividend; continuation of share buyback programme planned for 2026.

Peer Comparison

Revenue (TTM)

CAH stock ticker logoCAH
$250.55B
+12.8%
HUM stock ticker logoHUM
$137.20B
+14.1%
TAK stock ticker logoTAK
$30.18B
-0.7%

Gross Margin (Latest Quarter)

INSM stock ticker logoINSM
83.8%
-18.6pp
EW stock ticker logoEW
78.2%
-2.7pp
ZTS stock ticker logoZTS
71.7%
+2.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
BDX$53.49B36.44.5%34.0%
TAK$51.34B41.62.6%31.6%
EW$49.39B45.510.6%5.3%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.3%
Moderate Growth
4Q Net Income CAGR
7.7%
Profitability Improving
Cash Flow Stability
75%
Volatile Cash Flow

Deep Research

Next earnings:Jul 30, 2026
|
EPS:$0.28
|
Revenue:$7.59B
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data